Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan 英文参考文献.docVIP

下载本文档

4
0
约4.8万字
约 15页
2017-05-13 发布于上海
举报
版权申诉

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan 英文参考文献.doc

1、本文档共15页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan 英文参考文献

Pharmaceutics 2012, 4, 479-493; doi:10.3390/pharmaceutics4030479 OPEN ACCESS pharmaceutics ISSN 1999-4923 /journal/pharmaceutics Article Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan Tomomi Kimura 1,2,*, Kazuhito Shiosakai 2,3, Yasuaki Takeda 4, Shinji Takahashi 5, Masahiko Kobayashi 4 and Motonobu Sakaguchi 2 1 Epidemiology, Janssen Pharmaceutical K.K., 2-5-3, Nishi-Kanda, Chiyoda-ku, Tokyo 101-0065, Japan 2 Pro-Bono Pharmacoepidemiologists Committee in Japan, Japan 3 Clinical Data and Biostatistics, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan 4 Sales planning group, Japan Medical Research Institute Co. Ltd. 9-1 Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-6739, Japan 5 Nihon Chouzai Co. Ltd. 9-1 Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-6737, Japan * Author to whom correspondence should be addressed; E-Mail: tkimura1@; Tel.: +81-3-4411-5958; Fax: +81-3-4411-5086. Received: 11 June 2012; in revised form: 8 August 2012 / Accepted: 30 August 2012 / Published: 19 September 2012 Abstract: After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan. Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential risk factors. The Japan Association for Diabetes Education and Care (JADEC) released a recommendation in April 2010 to lower the dose of three major SUs (glimepiride, glibenclamide, and gliclazide) when adding a DPP-4 inhibitor. To evaluate the effectiveness of this risk minimization action along with labeling changes, dispensing records for 114,263 patients prescribed OHDs between December 2008 and December 2010 were identified in the Nihon-Chouzai pharmacy claims database. The adherence to the recommended dosing of SU co-pr